Guardant Health has been granted a patent for a system and method to detect rare mutations and copy number variations in cell-free polynucleotides. The method involves tagging parent polynucleotides, amplifying them, sequencing, collapsing reads, and analyzing for methylation profiles using bioinformatics processes. GlobalData’s report on Guardant Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Guardant Health, Personalized medicine biomarkers was a key innovation area identified from patents. Guardant Health's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Detection of rare mutations and copy number variations in polynucleotides
A recently granted patent (Publication Number: US11879158B2) outlines a method for analyzing methylation profiles in genetic material. The method involves converting cell-free nucleic acid into tagged parent polynucleotides with molecular barcodes, amplifying them, sequencing, collapsing the reads into consensus sequences, and analyzing them using bioinformatics to detect methylation profiles. The process includes determining polymorphic forms like methylation, hypermethylation, and hydroxymethylation. The initial genetic material can be obtained from various bodily samples like blood, plasma, urine, or stool, with specific quantities required for optimal results.
Furthermore, the patent details additional steps such as enriching the amplified polynucleotides for specific genomic regions of interest, mapping the sequencing reads to a reference sequence, and identifying somatic genetic variants like SNVs, indels, CNVs, or gene fusions. The method also allows for the detection of cancer based on the methylation profiles and the presence of somatic genetic variants in the subject's genetic material. By utilizing a combination of enzymatic ligation, molecular barcoding, and bioinformatics analysis, this patented method offers a comprehensive approach to studying genetic material for methylation patterns and cancer detection, potentially revolutionizing diagnostic and research applications in the field of genetics.
To know more about GlobalData’s detailed insights on Guardant Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
